Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
VNDA Quote, Financials, Valuation and Earnings
Last price:
$6.04
Seasonality move
:
50.09%
Day range:
$5.97 - $6.24
52-week range:
$3.81 - $9.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.64x
P/B ratio:
1.09x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
35.2%
Market cap:
$356.4M
Revenue:
$216.1M
EPS (TTM):
-$3.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 6.86% | -- | $13.63 |
|
ABBV
AbbVie, Inc.
|
$16.4B | $2.65 | 10.4% | 319.23% | $246.63 |
|
ANAB
AnaptysBio, Inc.
|
$87.1M | $0.93 | -26.24% | -13.87% | $67.92 |
|
AXSM
Axsome Therapeutics, Inc.
|
$192.8M | -$0.73 | 58.1% | -49.24% | $215.44 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.93% | 134.73% | $1,202.37 |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$0.06 | -- | -30.48% | $6.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$6.03 | $13.63 | $356.4M | -- | $0.00 | 0% | 1.64x |
|
ABBV
AbbVie, Inc.
|
$228.72 | $246.63 | $404.2B | 96.62x | $1.73 | 2.91% | 6.63x |
|
ANAB
AnaptysBio, Inc.
|
$54.83 | $67.92 | $1.5B | -- | $0.00 | 0% | 9.62x |
|
AXSM
Axsome Therapeutics, Inc.
|
$184.74 | $215.44 | $9.3B | -- | $0.00 | 0% | 16.20x |
|
LLY
Eli Lilly & Co.
|
$1,020.56 | $1,202.37 | $962.8B | 45.18x | $1.73 | 0.61% | 14.26x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
$3.79 | $6.83 | $645.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
3.72% | -0.805 | 2.42% | 2.24x |
|
ABBV
AbbVie, Inc.
|
104% | -0.239 | -- | 0.47x |
|
ANAB
AnaptysBio, Inc.
|
109.28% | 0.036 | 41.03% | 8.52x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.322 | 3.58% | 1.45x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.536 | 4.56% | 0.71x |
|
SLS
SELLAS Life Sciences Group, Inc.
|
1.3% | 0.100 | 0.3% | 7.50x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$49.6M | -$40.4M | -46.15% | -47.32% | -70.53% | -$29.5M |
|
ABBV
AbbVie, Inc.
|
$14B | $5.8B | 6.03% | 144.3% | 34.96% | $6.6B |
|
ANAB
AnaptysBio, Inc.
|
$75.7M | $34.7M | -22.38% | -367.62% | 45.47% | -$27.4M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
SLS
SELLAS Life Sciences Group, Inc.
|
-- | -$7.1M | -100.8% | -103.86% | -- | -$7.1M |
Vanda Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns VNDA or ABBV?
AbbVie, Inc. has a net margin of -246.76% compared to Vanda Pharmaceuticals, Inc.'s net margin of 10.92%. Vanda Pharmaceuticals, Inc.'s return on equity of -47.32% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M ABBVAbbVie, Inc.84.02% $1.02 $66.1B -
What do Analysts Say About VNDA or ABBV?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 125.95%. On the other hand AbbVie, Inc. has an analysts' consensus of $246.63 which suggests that it could grow by 7.83%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AbbVie, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ABBVAbbVie, Inc.13 9 0 -
Is VNDA or ABBV More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.622, which suggesting that the stock is 37.837% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.985%.
-
Which is a Better Dividend Stock VNDA or ABBV?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.91% to investors and pays a quarterly dividend of $1.73 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 279% of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ABBV?
Vanda Pharmaceuticals, Inc. quarterly revenues are $57.2M, which are smaller than AbbVie, Inc. quarterly revenues of $16.6B. Vanda Pharmaceuticals, Inc.'s net income of -$141.2M is lower than AbbVie, Inc.'s net income of $1.8B. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AbbVie, Inc.'s PE ratio is 96.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.64x versus 6.63x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.64x -- $57.2M -$141.2M ABBVAbbVie, Inc.6.63x 96.62x $16.6B $1.8B
-
Which has Higher Returns VNDA or ANAB?
AnaptysBio, Inc. has a net margin of -246.76% compared to Vanda Pharmaceuticals, Inc.'s net margin of 19.8%. Vanda Pharmaceuticals, Inc.'s return on equity of -47.32% beat AnaptysBio, Inc.'s return on equity of -367.62%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M ANABAnaptysBio, Inc.99.2% $0.52 $317M -
What do Analysts Say About VNDA or ANAB?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 125.95%. On the other hand AnaptysBio, Inc. has an analysts' consensus of $67.92 which suggests that it could grow by 23.87%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 ANABAnaptysBio, Inc.9 1 0 -
Is VNDA or ANAB More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.622, which suggesting that the stock is 37.837% less volatile than S&P 500. In comparison AnaptysBio, Inc. has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.645%.
-
Which is a Better Dividend Stock VNDA or ANAB?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnaptysBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AnaptysBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or ANAB?
Vanda Pharmaceuticals, Inc. quarterly revenues are $57.2M, which are smaller than AnaptysBio, Inc. quarterly revenues of $76.3M. Vanda Pharmaceuticals, Inc.'s net income of -$141.2M is lower than AnaptysBio, Inc.'s net income of $15.1M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AnaptysBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.64x versus 9.62x for AnaptysBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.64x -- $57.2M -$141.2M ANABAnaptysBio, Inc.9.62x -- $76.3M $15.1M
-
Which has Higher Returns VNDA or AXSM?
Axsome Therapeutics, Inc. has a net margin of -246.76% compared to Vanda Pharmaceuticals, Inc.'s net margin of -27.62%. Vanda Pharmaceuticals, Inc.'s return on equity of -47.32% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About VNDA or AXSM?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 125.95%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $215.44 which suggests that it could grow by 16.62%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 AXSMAxsome Therapeutics, Inc.16 1 0 -
Is VNDA or AXSM More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.622, which suggesting that the stock is 37.837% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.011%.
-
Which is a Better Dividend Stock VNDA or AXSM?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or AXSM?
Vanda Pharmaceuticals, Inc. quarterly revenues are $57.2M, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. Vanda Pharmaceuticals, Inc.'s net income of -$141.2M is lower than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.64x versus 16.20x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.64x -- $57.2M -$141.2M AXSMAxsome Therapeutics, Inc.16.20x -- $171M -$47.2M
-
Which has Higher Returns VNDA or LLY?
Eli Lilly & Co. has a net margin of -246.76% compared to Vanda Pharmaceuticals, Inc.'s net margin of 34.4%. Vanda Pharmaceuticals, Inc.'s return on equity of -47.32% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About VNDA or LLY?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 125.95%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,202.37 which suggests that it could grow by 17.82%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 LLYEli Lilly & Co.18 6 0 -
Is VNDA or LLY More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.622, which suggesting that the stock is 37.837% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock VNDA or LLY?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.61% to investors and pays a quarterly dividend of $1.73 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VNDA or LLY?
Vanda Pharmaceuticals, Inc. quarterly revenues are $57.2M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Vanda Pharmaceuticals, Inc.'s net income of -$141.2M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 45.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.64x versus 14.26x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.64x -- $57.2M -$141.2M LLYEli Lilly & Co.14.26x 45.18x $19.3B $6.6B
-
Which has Higher Returns VNDA or SLS?
SELLAS Life Sciences Group, Inc. has a net margin of -246.76% compared to Vanda Pharmaceuticals, Inc.'s net margin of --. Vanda Pharmaceuticals, Inc.'s return on equity of -47.32% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.
Company Gross Margin Earnings Per Share Invested Capital VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M SLSSELLAS Life Sciences Group, Inc.-- -$0.06 $46.2M -
What do Analysts Say About VNDA or SLS?
Vanda Pharmaceuticals, Inc. has a consensus price target of $13.63, signalling upside risk potential of 125.95%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 80.3%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than SELLAS Life Sciences Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VNDAVanda Pharmaceuticals, Inc.3 1 0 SLSSELLAS Life Sciences Group, Inc.2 0 0 -
Is VNDA or SLS More Risky?
Vanda Pharmaceuticals, Inc. has a beta of 0.622, which suggesting that the stock is 37.837% less volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.273, suggesting its more volatile than the S&P 500 by 127.327%.
-
Which is a Better Dividend Stock VNDA or SLS?
Vanda Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals, Inc. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VNDA or SLS?
Vanda Pharmaceuticals, Inc. quarterly revenues are $57.2M, which are larger than SELLAS Life Sciences Group, Inc. quarterly revenues of --. Vanda Pharmaceuticals, Inc.'s net income of -$141.2M is lower than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, Vanda Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals, Inc. is 1.64x versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VNDAVanda Pharmaceuticals, Inc.1.64x -- $57.2M -$141.2M SLSSELLAS Life Sciences Group, Inc.-- -- -- -$6.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 2.61% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is down 7.72% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 3.39% over the past day.
